The assay aims to identify inhibitors of the IDH1 gene mutation that is linked to secondary gliomas and AML. The mutation causes a loss of function in metabolizing isocitrate but gains the ability to produce oncometabolite 2HG, making it an oncogene. A fluorescent enzymatic assay has been designed to screen the NIH's MLSMR for potential inhibitors of IDH1. The goal is to develop new therapies for glioma and AML patients. Is the molecule effective to this assay?